Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565200 | 0.86 | P2RX7 (0.34) | RIPK1KDM4EALDH1A1 | |
| SCHEMBL564833 | 0.84 | NR3C1 (0.40) | SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL8824455 | 0.76 | KDM4E (0.42) | RIPK1KDM4EALDH1A1HPGD | |
| SCHEMBL1704764 | 0.75 | IDO1 (0.48) | RIPK1IDO1AGXTMAOBKDM4E | |
| SCHEMBL9074371 | 0.73 | RIPK1 (0.43) | RIPK1IDO1AGXTMAOBGSK3B | |
| SCHEMBL564639 | 0.72 | RIPK1 (0.39) | RIPK1MAOBDAOALDH1A1 | |
| SCHEMBL564882 | 0.72 | RIPK1 (0.46) | RIPK1IDO1AGXTMAOBKDM4E | |
| SCHEMBL30090103 | 0.72 | RIPK1 (0.46) | RIPK1IDO1AGXTMAOBKDM4E | |
| SCHEMBL564877 | 0.72 | IDO1 (0.50) | RIPK1IDO1AGXTMAOBKDM4E | |
| SCHEMBL19578985 | 0.71 | HDAC6 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765355-B1 | BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8044046-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-7786111-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | disclosed |
| US-7727984-B2 | R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino ]-ethyl}-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof; betamimetics; for administration once a day for treating COPD | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-1562603-B1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20090092558-A1 | 6-Hydroxy-8-{1-hydroxy-2-[2-(p-alkoxy- or carboxyalkoxyphenyl)-1,1-dimethylethylamino]ethyl}4H-benzo[1,4]oxazin-3-ones, e.g., 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]- ethyl}-4H-benzo[1,4]oxazin-3-one; betamimetics | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-09 | — | — | US | disclosed |
| EP-2025338-A1 | New medicaments for the treatment of chronic ostructive pulmonary disease | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-02-18 | — | — | EP | disclosed |
| US-20080293710-A1 | Aerosol formulation for the inhalation of beta-agonists | AVEN MICHAEL | 2008-11-27 | — | — | US | disclosed |
| US-20080167298-A1 | MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20070155741-A1 | Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-07-05 | — | — | US | disclosed |
| US-7056916-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-06 | — | — | US | disclosed |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167298-A1 | MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | RIPK1 4830/4885IDO1 2832/4885AGXT 1872/4885 |
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | ADRB1, ADRB2, ADRB3 | RIPK1 4864/4885IDO1 2974/4885AGXT 3258/4885 |
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | SLC26A4, CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RIPK1 4815/4885IDO1 3165/4885AGXT 2130/4885 |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | MRGPRX2, MRGPRX1, CFTR | RIPK1 4814/4885IDO1 2893/4885AGXT 958/4885 |
| US-20080293710-A1 | Aerosol formulation for the inhalation of beta-agonists | ADRB1, ADRB2, ADRB3 | RIPK1 4864/4885IDO1 2974/4885AGXT 3258/4885 |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | RIPK1 4830/4885IDO1 2838/4885AGXT 1887/4885 |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, CFTR | RIPK1 4814/4885IDO1 2893/4885AGXT 958/4885 |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | CLIC1, OTC, SLC10A1 | RIPK1 4721/4885IDO1 1760/4885AGXT 2295/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | RIPK1 4392/4885IDO1 2797/4885AGXT 1275/4885 |
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | ADRB1, ADRB2, ADRB3 | RIPK1 4864/4885IDO1 2974/4885AGXT 3258/4885 |
| US-20090092558-A1 | 6-Hydroxy-8-{1-hydroxy-2-[2-(p-alkoxy- or carboxyalkoxyphenyl)-1,1-dimethylethylamino]ethyl}4H-benzo[1,4]oxazin-3-ones, e.g., 6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]- ethyl}-4H-benzo[1,4]oxazin-3-one; betamimetics | CHRM1, CHRM2, ADRA2C | RIPK1 4851/4885IDO1 594/4885AGXT 2440/4885 |
| US-20070155741-A1 | Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | RIPK1 4830/4885IDO1 2838/4885AGXT 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.